473 A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.
http://www.pnas.org/content/110/47/19095.abstract
472 MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells.
http://www.pnas.org/content/110/47/19083.abstract
471 Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X
http://www.pnas.org/content/110/47/19077.abstract
470 A Ca2+-dependent signalling circuit regulates influenza A virus internalization and infection.
http://www.nature.com/ncomms/2013/131114/ncomms3763/full/ncomms3763.html
469 Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
http://www.nature.com/nature/journal/v503/n7475/full/nature12746.html
468 Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.
http://www.nature.com/nature/journal/v503/n7475/full/nature12744.html
467 Enzymes secreted by a bacterial pathogen turn immune responses against themselves.
http://www.sciencemag.org/content/342/6160/863.abstract
466 3D printing of microscopic bacterial communities.
http://www.pnas.org/content/110/46/18380.abstract
465 Aspartate is a primary nitrogen source for Mycobacterium tuberculosis during infection, being required for virulence after entering cells via the amino acid transporter AnsP1.
http://www.nature.com/nchembio/journal/v9/n11/abs/nchembio.1355.html
464 Tenascin-C is an innate broad-spectrum, HIV-1–neutralizing protein in breast milk.
http://www.pnas.org/content/110/45/18220.abstract
|
